AI Framework Discovers 7 New Lifespan-Extending Compounds Using Gene Expression Maps
Researchers built a transcriptomic model that predicted and validated 10 geroprotective compounds, 7 never before reported, extending lifespan in C. elegans.
Summary
Scientists at the National University of Singapore developed a computational model that identifies potential anti-aging compounds by analyzing how genes are expressed in groups — called coexpression modules — during aging. They mapped which of these modules are activated by known lifespan-extending interventions in C. elegans worms. Using this framework, they predicted 10 compounds likely to extend lifespan, then validated all 10 in living worms. Seven of those compounds had never previously been identified as geroprotective. RNA sequencing confirmed that the top candidates worked by targeting the same gene modules the model flagged. Crucially, several of these longevity-associated modules were also found in mice, where they correlated with frailty scores — suggesting the approach may translate to mammals and potentially humans.
Detailed Summary
Discovering drugs that slow aging is a challenge partly because no generalizable tool existed to predict whether a compound would extend healthy lifespan based on its molecular fingerprint. This study addresses that gap with a novel computational framework built on transcriptomic data.
Researchers deconstructed the aging transcriptome of Caenorhabditis elegans into coexpression modules — clusters of genes that rise and fall together. They then identified which modules are consistently modulated by established lifespan-extending interventions, labeling these "longevity-associated aging modules." The key insight was that beneficial, adaptive transcriptomic shifts occur naturally during aging, and compounds that reinforce those shifts may confer geroprotection.
Using this module-based model, the team screened candidate compounds computationally and selected 10 for experimental validation. All 10 significantly extended lifespan in C. elegans — a remarkable hit rate. Seven of the 10 had no prior record as geroprotective agents, representing genuine novel discoveries. RNA sequencing of the two best-performing candidates confirmed that both compounds specifically modulated the longevity-associated modules the model had targeted, validating the mechanistic logic of the approach.
A critical translational finding emerged when the researchers examined mouse data: several of the worm longevity modules had conserved counterparts in mice, and activity in those mouse modules correlated with frailty. This cross-species conservation suggests the framework is not limited to invertebrate biology and could guide geroprotector discovery in mammals.
Caveats are notable. The study relies on C. elegans as its primary validation organism, which has significant physiological differences from humans. Conservation in mice is correlational, not mechanistic. The full paper was not available for review; this summary is based on the published abstract. Nonetheless, the approach — using transcriptomic module signatures to predict and validate geroprotectors — offers a replicable, scalable pipeline that could accelerate longevity drug discovery substantially.
Key Findings
- A transcriptomic module model predicted 10 lifespan-extending compounds; all 10 were experimentally validated in C. elegans.
- Seven of the 10 validated compounds are newly identified geroprotectors with no prior anti-aging record.
- RNA sequencing confirmed top candidates work by specifically modulating the targeted longevity-associated gene modules.
- Several longevity modules are conserved in mice and correlate with frailty, suggesting mammalian translational potential.
- Beneficial transcriptomic adaptations occur naturally during aging and can be amplified pharmacologically.
Methodology
The team used coexpression network analysis to decompose the C. elegans aging transcriptome into modules, then identified those consistently altered by known lifespan-extending interventions. Predicted compounds were experimentally validated for lifespan extension in C. elegans, with RNA sequencing performed on top candidates to confirm on-target module modulation. Cross-species conservation was assessed in mouse datasets correlated with frailty measures.
Study Limitations
All lifespan validation was performed in C. elegans, a short-lived invertebrate with significant physiological differences from humans; mammalian lifespan effects remain untested. The mouse findings are correlational and do not establish causality between module activity and frailty outcomes. This summary is based on the abstract only, as the full paper was not openly accessible; methodological details and the identities of the 7 novel compounds could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: